Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666848 · ClinicalTrials.gov registry record · Phase 4
Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome
A Phase 4 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT00666848: Completed Phase 4 study, sponsored by Vanderbilt University.
NCT00666848 is a Phase 4 study that has completed, run by Vanderbilt University. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666848, a Phase 4 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome. We will also measure the effect of sitagliptin on blood pressure in people already taking a blood pressure medication called an ACE inhibitor.
Primary Outcome
The change in mean arterial pressure (MAP) in response to placebo or enalapril after pretreatment with 5 days of placebo
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Enalapril 5mg
- DRUG Enalapril 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
What the finished NCT00666848 record still lists
NCT00666848 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00666848 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00666848 about?
NCT00666848 is a clinical study titled "Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome". This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome. We will also measure the effect of sitagliptin on blood pressure in people already taking a blood pressure medication called an ACE inhibitor.
What is the current status of trial NCT00666848?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2008-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00666848?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Enalapril 5mg (DRUG), Enalapril 10mg (DRUG).
Who is sponsoring clinical trial NCT00666848?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00666848's enrollment target sits among peer trials
24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia